Limits...
Keratinocyte growth factor-2 intratracheal instillation significantly attenuates ventilator-induced lung injury in rats.

Bi J, Tong L, Zhu X, Yang D, Bai C, Song Y, She J - J. Cell. Mol. Med. (2014)

Bottom Line: Inflammatory cytokines (tumour necrosis factor-α, macrophage inflammatory protein 2), neutrophil and total protein levels in bronchoalveolar lavage fluid and surfactant protein mRNA expression in lung tissue were detected; the number of alveolar type II cells, lung water content and lung morphology were also evaluated.The results indicate that pre-treatment with KGF-2 showed dramatic improvement in lung oedema and inflammation compared with HVZP alone, together with increased surfactant protein mRNA and alveolar type II cells.Our results suggest that KGF-2 might be considered a promising prevention for human VILI or other acute lung injury diseases.

View Article: PubMed Central - PubMed

Affiliation: Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.

Show MeSH

Related in: MedlinePlus

Images of immunohistochemistry for SP-C. (A) control group: Normal rat lung histologic section after intratracheal administration of PBS; (B) KGF-2 group: Marked alveolar type II cell (ATII) hyperplasia is seen after intratracheal administration of KGF-2; (C) HVZP group: alveolar type II cell decreased in lungs subjected to an injurious ventilatory strategy; (D) HVZP+KGF-2 group: KGF-2 pre-treatment increased alveolar type II cell counts for lungs subjected to an injurious ventilatory strategy (×400). (E) Alveolar type II cell counts. Alveolar type II cell count in HVZP group was significantly lower than those in control group (P < 0.05). KGF-2 pre-treatment significantly increased alveolar type II cell count compared with the HVZP group (P < 0.05). *P < 0.05 versus control group; †P < 0.05 versusHVZP group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4508161&req=5

fig03: Images of immunohistochemistry for SP-C. (A) control group: Normal rat lung histologic section after intratracheal administration of PBS; (B) KGF-2 group: Marked alveolar type II cell (ATII) hyperplasia is seen after intratracheal administration of KGF-2; (C) HVZP group: alveolar type II cell decreased in lungs subjected to an injurious ventilatory strategy; (D) HVZP+KGF-2 group: KGF-2 pre-treatment increased alveolar type II cell counts for lungs subjected to an injurious ventilatory strategy (×400). (E) Alveolar type II cell counts. Alveolar type II cell count in HVZP group was significantly lower than those in control group (P < 0.05). KGF-2 pre-treatment significantly increased alveolar type II cell count compared with the HVZP group (P < 0.05). *P < 0.05 versus control group; †P < 0.05 versusHVZP group.

Mentions: Surfactant protein-C immunoreactivities were mainly detected in alveolar type II cells, and the immunoreactivity markedly decreased in rats treated with HVZP when compared with the control groups (P < 0.05, Fig.3). Keratinocyte growth factor-2 pre-treatment significantly increased the number of alveolar type II cells (P < 0.05, Fig.3). On the other hand, mRNA expression of SP-A, SP-B and SP-C were significantly lower in HVZP group than control group (P < 0.05, Fig.4A–C), but KGF-2 pre-treatment significantly increased the level of SP-A, SP-B and SP-C mRNA expression group (P < 0.05, Fig.4A–C).


Keratinocyte growth factor-2 intratracheal instillation significantly attenuates ventilator-induced lung injury in rats.

Bi J, Tong L, Zhu X, Yang D, Bai C, Song Y, She J - J. Cell. Mol. Med. (2014)

Images of immunohistochemistry for SP-C. (A) control group: Normal rat lung histologic section after intratracheal administration of PBS; (B) KGF-2 group: Marked alveolar type II cell (ATII) hyperplasia is seen after intratracheal administration of KGF-2; (C) HVZP group: alveolar type II cell decreased in lungs subjected to an injurious ventilatory strategy; (D) HVZP+KGF-2 group: KGF-2 pre-treatment increased alveolar type II cell counts for lungs subjected to an injurious ventilatory strategy (×400). (E) Alveolar type II cell counts. Alveolar type II cell count in HVZP group was significantly lower than those in control group (P < 0.05). KGF-2 pre-treatment significantly increased alveolar type II cell count compared with the HVZP group (P < 0.05). *P < 0.05 versus control group; †P < 0.05 versusHVZP group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4508161&req=5

fig03: Images of immunohistochemistry for SP-C. (A) control group: Normal rat lung histologic section after intratracheal administration of PBS; (B) KGF-2 group: Marked alveolar type II cell (ATII) hyperplasia is seen after intratracheal administration of KGF-2; (C) HVZP group: alveolar type II cell decreased in lungs subjected to an injurious ventilatory strategy; (D) HVZP+KGF-2 group: KGF-2 pre-treatment increased alveolar type II cell counts for lungs subjected to an injurious ventilatory strategy (×400). (E) Alveolar type II cell counts. Alveolar type II cell count in HVZP group was significantly lower than those in control group (P < 0.05). KGF-2 pre-treatment significantly increased alveolar type II cell count compared with the HVZP group (P < 0.05). *P < 0.05 versus control group; †P < 0.05 versusHVZP group.
Mentions: Surfactant protein-C immunoreactivities were mainly detected in alveolar type II cells, and the immunoreactivity markedly decreased in rats treated with HVZP when compared with the control groups (P < 0.05, Fig.3). Keratinocyte growth factor-2 pre-treatment significantly increased the number of alveolar type II cells (P < 0.05, Fig.3). On the other hand, mRNA expression of SP-A, SP-B and SP-C were significantly lower in HVZP group than control group (P < 0.05, Fig.4A–C), but KGF-2 pre-treatment significantly increased the level of SP-A, SP-B and SP-C mRNA expression group (P < 0.05, Fig.4A–C).

Bottom Line: Inflammatory cytokines (tumour necrosis factor-α, macrophage inflammatory protein 2), neutrophil and total protein levels in bronchoalveolar lavage fluid and surfactant protein mRNA expression in lung tissue were detected; the number of alveolar type II cells, lung water content and lung morphology were also evaluated.The results indicate that pre-treatment with KGF-2 showed dramatic improvement in lung oedema and inflammation compared with HVZP alone, together with increased surfactant protein mRNA and alveolar type II cells.Our results suggest that KGF-2 might be considered a promising prevention for human VILI or other acute lung injury diseases.

View Article: PubMed Central - PubMed

Affiliation: Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.

Show MeSH
Related in: MedlinePlus